Dendreon Prostate Cancer Therapy Studies To Be Complete This Summer
A Phase II trial of Dendreon's dendritic cell therapy in the treatment of patients with prostate cancer is scheduled to be completed by the end of the summer, the company says.
A Phase II trial of Dendreon's dendritic cell therapy in the treatment of patients with prostate cancer is scheduled to be completed by the end of the summer, the company says.